$4000 | Single User
$8000 | Site License
$8000 | Global License

Global PCSK9 Inhibitors Market Status and Outlook 2018-2025 [Report Updated: 13-08-2018]

Published by 99Strategy: 13 Aug 2018 | 217510 | In Stock

Introduction

Report Snapshot

Key Content of Chapters (Including and can be customized, report is a semifinished version, and it takes 48-72 hours to upgrade)

Part 1:

Terminology Definition, Industry Chain,Industry Dynamics & Regulations and Global Market Overview

Part 2:

Upstream (Raw Materials / Components) & Manufacturing (Procurement Methods & Channels and Cost) , Major Regional Production Overview and Trade Flow

Part 3:

Product Segment Overview and Market Status

Part 4:

Application / End-User Segment Overview and Market Status

Part 5:

Region Segment Overview and Market Status

Part 6:

Product & Application Segment Production & Demand by Region

Part 7:

Market Forecast by Product, Application & Region

Part 8:

Company information, Products & Services and Business Operation (Sales, Cost, Margin etc.)

Part 9:

Market Competition and Environment for New Entrants

Part 10:

Conclusion

Market Segment as follows:

Key Companies

Amgen

Eli Lilly

Sanofi

Pfizer

Novartis

Roche

Merck

Alnylam

AstraZeneca

Affiris

BMS

Ionis Pharmaceuticals

Cyon Therapeutics

Daiichi Sankyo

Market by Type

Epatha Evolocumab

Praluent Alirocumab

Bococizumab

Others

Market by Application

Clinical Application

Drug Development

Others

Table of Contents
for Global PCSK9 Inhibitors Market Status and Outlook 2018-2025 [Report Updated: 13-08-2018]

  • Table of Contents

    Part 1 Industry Overview (200 USD)

    1.1 PCSK9 Inhibitors Industry

    1.1.1 Market Development

    1.1.2 Terminology Definition in the Report

    1.1.2.1 Production

    1.1.2.2 Demand

    1.1.2.3 Sales Revenue

    1.1.2.4 Ex-factory Price & Sales Price

    1.1.2.5 Cost

    1.1.2.6 Gross Margin

    1.2 Products & Services Scope

    1.3 Industry Chain

    1.4 Industry Dynamics & Regulations

    1.5 Global Market Overview

    Part 2 Upstream & Production (200 USD)

    2.1 Raw Materials / Components

    2.2 Procurement Methods & Channels

    2.3 Cost Structure & Manufacturing

    2.4 Industry Capacity

    2.5 Production Distribution by Geography

    2.5.1 Production in Major Regions / Countries

    2.5.2 Trade Flow Overview

    Part 3 Product Segment (400 USD)

    3.1 Introduction by Type

    3.1.1 Epatha Evolocumab

    3.1.2 Praluent Alirocumab

    3.1.3 Bococizumab

    3.1.4 Others

    3.2 Market Status

    Part 4 Application / End-User Segment (400 USD)

    4.1 Introduction by Application

    4.1.1 Clinical Application

    4.1.2 Drug Development

    4.1.3 Others

    4.2 Market Status

    Part 5 Regional Market (600 USD)

    5.1 Market Overview

    5.2 by Region

    5.2.1 North America

    5.2.1.1 United States Market Size and Growth (2015-2018E)

    5.2.1.2 Canada Market Size and Growth (2015-2018E)

    5.2.1.3 Mexico Market Size and Growth (2015-2018E)

    5.2.2 Europe

    5.2.2.1 Germany Market Size and Growth (2015-2018E)

    5.2.2.2 UK Market Size and Growth (2015-2018E)

    5.2.2.3 France Market Size and Growth (2015-2018E)

    5.2.2.4 Italy Market Size and Growth (2015-2018E)

    5.2.2.5 Spain Market Size and Growth (2015-2018E)

    5.2.2.6 Netherlands Market Size and Growth (2015-2018E)

    5.2.2.7 Poland Market Size and Growth (2015-2018E)

    5.2.2.8 Belgium Market Size and Growth (2015-2018E)

    5.2.2.9 Sweden Market Size and Growth (2015-2018E)

    5.2.2.10 Austria Market Size and Growth (2015-2018E)

    5.2.2.11 Denmark Market Size and Growth (2015-2018E)

    5.2.2.12 Switzerland Market Size and Growth (2015-2018E)

    5.2.2.13 Russia Market Size and Growth (2015-2018E)

    5.2.3 Asia-Pacific

    5.2.3.1 China Market Size and Growth (2015-2018E)

    5.2.3.2 India Market Size and Growth (2015-2018E)

    5.2.3.3 Japan Market Size and Growth (2015-2018E)

    5.2.3.4 Korea Market Size and Growth (2015-2018E)

    5.2.3.5 Australia Market Size and Growth (2015-2018E)

    5.2.3.6 Indonesia Market Size and Growth (2015-2018E)

    5.2.3.7 Thailand Market Size and Growth (2015-2018E)

    5.2.3.8 Malaysia Market Size and Growth (2015-2018E)

    5.2.3.9 Singapore Market Size and Growth (2015-2018E)

    5.2.3.10 Philippines Market Size and Growth (2015-2018E)

    5.2.4 South America

    5.2.4.1 Brazil Market Size and Growth (2015-2018E)

    5.2.4.2 Argentina Market Size and Growth (2015-2018E)

    5.2.4.3 Columbia Market Size and Growth (2015-2018E)

    5.2.4.4 Chile Market Size and Growth (2015-2018E)

    5.2.4.5 Peru Market Size and Growth (2015-2018E)

    5.2.4.6 Puerto Rico Market Size and Growth (2015-2018E)

    5.2.4.7 Ecuador Market Size and Growth (2015-2018E)

    5.2.5 Middle East

    5.2.5.1 Saudi Arabia Market Size and Growth (2015-2018E)

    5.2.5.2 Iran Market Size and Growth (2015-2018E)

    5.2.5.3 UAE Market Size and Growth (2015-2018E)

    5.2.5.4 Oman Market Size and Growth (2015-2018E)

    5.2.5.5 Kuwait Market Size and Growth (2015-2018E)

    5.2.5.6 Iraq Market Size and Growth (2015-2018E)

    5.2.5.7 Turkey Market Size and Growth (2015-2018E)

    5.2.6 Africa

    5.2.6.1 South Africa Market Size and Growth (2015-2018E)

    5.2.6.2 Egypt Market Size and Growth (2015-2018E)

    5.2.6.3 Nigeria Market Size and Growth (2015-2018E)

    5.2.6.4 Algeria Market Size and Growth (2015-2018E)

    5.2.6.5 Angola Market Size and Growth (2015-2018E)

    5.2.6.6 Morocco Market Size and Growth (2015-2018E)

    5.2.6.7 Sultan Market Size and Growth (2015-2018E)

    Part 6 Market Subdivision (800 USD)

    6.1 Regional Production

    6.1.1 Production by Type

    6.1.1.1 Epatha Evolocumab Production by Region

    6.1.1.2 Praluent Alirocumab Production by Region

    6.1.1.3 Bococizumab Production by Region

    6.1.1.4 Others Production by Region

    6.1.2 Production by Application

    6.1.2.1 Clinical Application Production by Region

    6.1.2.2 Drug Development Production by Region

    6.1.2.3 Others Production by Region

    6.2 Regional Demand

    6.2.1 Demand by Type

    6.2.1.1 Epatha Evolocumab Demand by Region

    6.2.1.2 Praluent Alirocumab Demand by Region

    6.2.1.3 Bococizumab Demand by Region

    6.2.1.4 Others Demand by Region

    6.2.2 Demand by Application

    6.2.2.1 Clinical Application Demand by Region

    6.2.2.2 Drug Development Demand by Region

    6.2.2.3 Others Demand by Region

    Part 7 Market Forecast (200 USD)

    7.1 Global Forecast

    7.2 Forecast by Type

    7.3 Forecast by Application

    7.4 Forecast by Region

    Part 8 Key Companies List (600 USD)

    8.1 Amgen

    8.1.2 Company Information

    8.1.2 Products & Services

    8.1.3 Business Operation

    8.2 Eli Lilly

    8.2.1 Company Information

    8.2.2 Products & Services

    8.2.3 Business Operation

    8.3 Sanofi

    8.3.1 Company Information

    8.3.2 Products & Services

    8.3.3 Business Operation

    8.4 Pfizer

    8.4.1 Company Information

    8.4.2 Products & Services

    8.4.3 Business Operation

    8.5 Novartis

    8.5.1 Company Information

    8.5.2 Products & Services

    8.5.3 Business Operation

    8.6 Roche

    8.6.1 Company Information

    8.6.2 Products & Services

    8.6.3 Business Operation

    8.7 Merck

    8.7.1 Company Information

    8.7.2 Products & Services

    8.7.3 Business Operation

    8.8 Alnylam

    8.8.1 Company Information

    8.8.2 Products & Services

    8.8.3 Business Operation

    8.9 AstraZeneca

    8.9.1 Company Information

    8.9.2 Products & Services

    8.9.3 Business Operation

    8.10 Affiris

    8.10.1 Company Information

    8.10.2 Products & Services

    8.10.3 Business Operation

    8.11 BMS

    8.12 Ionis Pharmaceuticals

    8.13 Cyon Therapeutics

    8.14 Daiichi Sankyo

    Part 9 Company Competition (500 USD)

    9.1 Market by Company

    9.2 Price & Gross Margin

    9.3 Competitive Environment for New Entrants

    9.3.1 Michael Porter's Five Forces Model

    9.3.2 SWOT

    Part 10 Research Conclusion (100 USD)

List Of Tables
in Global PCSK9 Inhibitors Market Status and Outlook 2018-2025 [Report Updated: 13-08-2018]

Table PCSK9 Inhibitors Industry Dynamics & Regulations List

Table Global PCSK9 Inhibitors Sales Revenue, Cost and Margin, 2015-2018E

Table Global PCSK9 Inhibitors Market Status by Type 2015-2018E, in USD Million

Table Global PCSK9 Inhibitors Market Status by Application 2015-2018E, in USD Million

Table Global PCSK9 Inhibitors Market Status by Application 2015-2018E, in Volume

Table Global PCSK9 Inhibitors Market by Region 2015-2018E, in USD Million

Table Global PCSK9 Inhibitors Market Share by Region in 2018, in USD Million

Table Global PCSK9 Inhibitors Market by Region 2015-2018E, in Volume

Table Global PCSK9 Inhibitors Market Share by Region in 2018, in Volume

Table Epatha Evolocumab Production Value by Region 2015-2018E, in USD Million

Table Epatha Evolocumab Production Volume by Region 2015-2018E, in Volume

Table Praluent Alirocumab Production Value by Region 2015-2018E, in USD Million

Table Praluent Alirocumab Production Volume by Region 2015-2018E, in Volume

Table Bococizumab Production Value by Region 2015-2018E, in USD Million

Table Bococizumab Production Volume by Region 2015-2018E, in Volume

Table Others Production Value by Region 2015-2018E, in USD Million

Table Others Production Volume by Region 2015-2018E, in Volume

Table Clinical Application Production Value by Region 2015-2018E, in USD Million

Table Clinical Application Production Volume by Region 2015-2018E, in Volume

Table Drug Development Production Value by Region 2015-2018E, in USD Million

Table Drug Development Production Volume by Region 2015-2018E, in Volume

Table Others Production Value by Region 2015-2018E, in USD Million

Table Others Production Volume by Region 2015-2018E, in Volume

Table Epatha Evolocumab Market Size by Region 2015-2018E, in USD Million

Table Epatha Evolocumab Market Size by Region 2015-2018E, in Volume

Table Praluent Alirocumab Market Size by Region 2015-2018E, in USD Million

Table Praluent Alirocumab Market Size by Region 2015-2018E, in Volume

Table Bococizumab Market Size by Region 2015-2018E, in USD Million

Table Bococizumab Market Size by Region 2015-2018E, in Volume

Table Others Market Size by Region 2015-2018E, in USD Million

Table Others Market Size by Region 2015-2018E, in Volume

Table Clinical Application Market Size by Region 2015-2018E, in USD Million

Table Clinical Application Market Size by Region 2015-2018E, in Volume

Table Drug Development Market Size by Region 2015-2018E, in USD Million

Table Drug Development Market Size by Region 2015-2018E, in Volume

Table Others Market Size by Region 2015-2018E, in USD Million

Table Others Market Size by Region 2015-2018E, in Volume

Table GlobalPCSK9 Inhibitors Forecast by Type 2019F-2025F, in USD Million

Table PCSK9 Inhibitors Forecast by Type 2019F-2025F, in Volume

Table PCSK9 Inhibitors Market Forecast by Application / End-User 2019F-2025F, in USD Million

Table PCSK9 Inhibitors Market Forecast by Application / End-User 2019F-2025F, in Volume

Table PCSK9 Inhibitors Market Forecast by Region 2019F-2025F, in USD Million

Table PCSK9 Inhibitors Market Forecast by Region 2019F-2025F, in Volume

Table Amgen Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Amgen

Table Eli Lilly Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Eli Lilly

Table Sanofi Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Sanofi

Table Pfizer Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Pfizer

Table Novartis Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Novartis

Table Roche Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Roche

Table Merck Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Merck

Table Alnylam Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Alnylam

Table AstraZeneca Information

Table PCSK9 Inhibitors Sales, Cost, Margin of AstraZeneca

Table Affiris Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Affiris

Table BMS Information

Table PCSK9 Inhibitors Sales, Cost, Margin of BMS

Table Ionis Pharmaceuticals Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Ionis Pharmaceuticals

Table Cyon Therapeutics Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Cyon Therapeutics

Table Daiichi Sankyo Information

Table PCSK9 Inhibitors Sales, Cost, Margin of Daiichi Sankyo

Table Global PCSK9 Inhibitors Sales Revenue by Company 2015-2017, in USD Million

Table Global PCSK9 Inhibitors Sales Volume by Company 2015-2017, in Volume

Table Global PCSK9 Inhibitors Sales Volume by Company in 2018, in Volume

List Of Figures, Charts and Diagrams
in Global PCSK9 Inhibitors Market Status and Outlook 2018-2025 [Report Updated: 13-08-2018]

Figure PCSK9 Inhibitors Picture

Figure PCSK9 Inhibitors Industry Chain Diagram

Figure Global PCSK9 Inhibitors Sales Revenue 2015-2018E, in USD Million

Figure Global PCSK9 Inhibitors Sales Volume 2015-2018E, in Volume

Figure Global PCSK9 Inhibitors Market Status by Type 2015-2018E, in Volume

Figure North America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million

Figure North America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume

Figure Europe PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million

Figure Europe PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume

Figure Asia-Pacific PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million

Figure Asia-Pacific PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume

Figure South America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million

Figure South America PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume

Figure Middle East PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million

Figure Middle East PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume

Figure Africa PCSK9 Inhibitors Market Size and Growth 2015-2018E, in USD Million

Figure Africa PCSK9 Inhibitors Market Size and Growth 2015-2018E, in Volume

Figure Global PCSK9 Inhibitors Sales Revenue Forecast 2019F-2025F, in USD Million

Figure Global PCSK9 Inhibitors Sales Volume Forecast 2019F-2025F, in Volume

Figure Global PCSK9 Inhibitors Sales Price Forecast 2019F-2025F

Figure Global PCSK9 Inhibitors Gross Margin Forecast 2019F-2025F

Figure Global PCSK9 Inhibitors Sales Revenue by Company in 2018, in USD Million

Figure Global PCSK9 Inhibitors Price by Company in 2018

Figure Global PCSK9 Inhibitors Gross Margin by Company in 2018

Additional Details

Publisher

99Strategy

Publisher Information

99Strategy is a well-known independent third party market research consulting company in China. We are committed to providing professional solutions for corporate strategic decision-making, we operate three business department of market research, custom survey and Investment & financing, mainly covering research report, market survey, competitive survey, market channel investigation, market entry research, consumer research, global market research, business Plan, project feasibility study, and investment research, special market solutions, industry plan consulting, company strategic planning, sales consulting, management consulting and other services.



99Strategy has many professionals in market research, and are familiar with the market reports in the field.

Reference

217510 | 99SHea2018410013

Number of Pages

155

Report Format

PDF

99Strategy Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
24 Apr 2018 by Global Markets Direct USD $3,500 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insight, 2018
“Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2018” report by...
14 Feb 2018 by Delve Insight USD $1,250 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
10 Oct 2017 by Global Markets Direct USD $3,500 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor-Mechanism of action...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights,...
30 May 2017 by Delve Insight USD $1,250 More Info
Physician Views: Repatha recommended for European approval – how will EU5 cardiologists utilise the PCSK9 inhibitor class?
ScopeAmgen and Sanofi/Regeneron Pharmaceuticals may be locked in one of the most intriguing US drug ...
01 May 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Is Esperion's ETC-1002 a viable threat to the PCSK9 inhibitors if mid-stage data are replicated in Phase III studies?
Scope Last week saw Esperion Therapeutics release promising Phase IIb data for its oral hypercholest...
25 Mar 2015 by FirstWord Pharma USD $695 More Info
Physician Views: Do cardiologists agree with payer rhetoric on PCSK9 inhibitors?
Scope Last week, CVS Health became the second pharmacy benefit manager (PBM) to publicly highlight t...
25 Feb 2015 by FirstWord Pharma USD $695 More Info
Physician Views: As race to market intensifies, how expectant are cardiologists for PCSK9 inhibitor class?
Scope The race to successfully deliver a PCSK9 inhibitor to market for the treatment of hypercholest...
07 Aug 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life beyond statins – what opportunity for PCSK9 inhibitors?
ScopeWith Sanofi and Regeneron Pharmaceuticals set to unveil the first Phase III data for their expe...
01 Oct 2013 by FirstWord Pharma USD $695 More Info

This report is published by 99Strategy

99Strategy is a well-known independent third party market research consulting company in China. We are committed to providing professional solutions for corporate strategic decision-making, we operate three business department of market research, custom survey and Investment & financing, mainly covering research report, market survey, competitive survey, market channel investigation, market entry research, consumer research, global market research, business Plan, project feasibility study, and investment research, special market solutions, industry plan consulting, company strategic planning, sales consulting, management consulting and other services.

99Strategy has many professionals in market research, and are familiar with the market reports in the field.

Download Free Report Summary PDF

Global PCSK9 Inhibitors Market Status and Outlook 2018-2025 [Report Updated: 13-08-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data